Dernières nouvelles pour aTyr Pharma (NASDAQ:ATYR) Stock

ATYR PHARMA INC

aTyr Pharma

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

aTyr Pharma Inc

<p>Energy Transfer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) has outperformed the market over the past 5 years by 7.32% on an annualized basis producing an average annual return of 20.82%. Currently, Energy Transfer has a market capitalization of $61.22 billion. </p>
<p><strong>Buying $1000 In ET:</strong> If an investor had bought $1000 of ET stock 5 years ago, it would be worth <strong>$2,639.47</strong> today based on a price of $17.84 for ET at the time of writing.</p>
<h3>Energy Transfer's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754086528_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


News

Trading Ideas

Here's How Much You Would Have Made Owning Energy Transfer Stock In The Last 5 Years

<p><a href="https://trumpstruth.org/statuses/32342">https://trumpstruth.org/statuses/32342</a></p>


Politics

Economics

General

President Trump Posts On Truth Social ""Too Late" Powell should resign, just like Adriana Kugler, a Biden Appointee, resigned. She knew he was doing the wrong thing on Interest Rates. He should resign, also!"

<p>Jones Trading  analyst Jason Weaver   maintains AG Mortgage IT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MITT#NYSE">MITT</a>) with a Buy and maintains $8 price target.</p>


Price Target

Analyst Ratings

MITT

Jones Trading Maintains Buy on AG Mortgage IT, Maintains $8 Price Target

<p>4 analysts have expressed a variety of opinions on AppFolio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPF#NASDAQ">APPF</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $301.75, with a high estimate of $350.00 and a low estimate of $240.00. Surpassing the previous average price target of $217.67, the current average has increased by 38.63%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754085902_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The standing of AppFolio among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Announces</td>
<td>Buy</td>
<td>$350.00</td>
<td>-</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Ryan Tomasello</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$267.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$240.00</td>
<td>$208.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to AppFolio. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of AppFolio compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of AppFolio's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into AppFolio's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/APPF/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on AppFolio analyst ratings.</strong></a></p>
<h2>Get to Know AppFolio Better</h2>
<p>AppFolio Inc provides cloud-based software solutions for the real estate industry. Its property management software offers property managers an end-to-end solution to their business needs. The group's products include cloud-based property management software (Appfolio Property Manager). Its solutions are AppFolio Property Manager Core, AppFolio Property Manager Plus, and AppFolio Property Manager Max. It also offers value-added services, such as screening, risk mitigation, and electronic payment services. Its markets are Single-Family, Multifamily, Student Housing, Affordable Housing, Community Associations, Commercial, and Investment Management. The business activity of the firm predominantly functions in the United States and it generates revenue in the form of subscription fees.</p>
<h3>Understanding the Numbers: AppFolio's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Over the 3M period, AppFolio showcased positive performance, achieving a revenue growth rate of <strong>16.15%</strong> as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>14.42%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> AppFolio's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>6.4%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>5.27%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> AppFolio's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.09</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


APPF

What 4 Analyst Ratings Have To Say About AppFolio

<p>DA Davidson  analyst Matt Summerville   maintains AMETEK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AME#NYSE">AME</a>) with a Buy and raises the price target from $210 to $215.</p>


DA Davidson Maintains Buy on AMETEK, Raises Price Target to $215

<p>Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on BorgWarner (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWA#NYSE">BWA</a>) in the last three months.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for BorgWarner, revealing an average target of $40.55, a high estimate of $46.00, and a low estimate of $32.00. This upward trend is evident, with the current average reflecting a 9.86% increase from the previous average price target of $36.91.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754085857_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The standing of BorgWarner among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colin Langan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$46.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Alexander Potter</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$44.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Dan Levy</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Joseph Spak</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>David Leiker</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$39.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Colin Langan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>John Murphy</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$41.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Alexander Potter</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$37.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Colin Langan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$44.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Joseph Spak</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>David Leiker</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$32.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to BorgWarner. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of BorgWarner compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of BorgWarner's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BWA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on BorgWarner analyst ratings.</strong></a></p>
<h2>Delving into BorgWarner's Background</h2>
<p>BorgWarner is a tier one supplier of turbo and thermal management technologies, drivetrain systems, powerdrive systems, and battery and charging systems mostly to automotive original equipment manufacturers. Its products aim to move a vehicle with as few electrons as possible, resulting in cleaner, cost-optimized, and more-efficient vehicles. Foundational products, the combustion vehicle business, contributes more than 80% to group revenue while BorgWarner transitions to becoming an electric vehicle-centric parts supplier (e-business). In 2023, 25% of the company's revenue was sourced from Volkswagen and Ford. Revenue is well diversified geographically, with approximately a third each generated in North America, Europe, and Asia.</p>
<h3>BorgWarner: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> BorgWarner's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately <strong>-2.23%</strong>. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> BorgWarner's net margin is impressive, surpassing industry averages. With a net margin of <strong>4.47%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> BorgWarner's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>2.79%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> BorgWarner's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.13%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> BorgWarner's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.71</strong>.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Deep Dive Into BorgWarner Stock: Analyst Perspectives (11 Ratings)

<p>Across the recent three months, 5 analysts have shared their insights on 4D Molecular Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $31.4, a high estimate of $44.00, and a low estimate of $25.00. Experiencing a 9.77% decline, the current average is now lower than the previous average price target of $34.80. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754085841_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The standing of 4D Molecular Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$44.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$38.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to 4D Molecular Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of 4D Molecular Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of 4D Molecular Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of 4D Molecular Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FDMT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on 4D Molecular Therapeutics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Get to Know 4D Molecular Therapeutics Better</h2>
<p>4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.</p>
<h3>Financial Milestones: 4D Molecular Therapeutics's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Decline in Revenue:</strong> Over the 3M period, 4D Molecular Therapeutics faced challenges, resulting in a decline of approximately <strong>-50.0%</strong> in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> 4D Molecular Therapeutics's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-342657.14%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-9.79%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> 4D Molecular Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-8.92%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> 4D Molecular Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of <b>0.05</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


FDMT

Assessing 4D Molecular Therapeutics: Insights From 5 Financial Analysts

<p>Across the recent three months, 5 analysts have shared their insights on Vulcan Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMC#NYSE">VMC</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Vulcan Materials, revealing an average target of $298.0, a high estimate of $318.00, and a low estimate of $279.00. This current average has increased by 4.41% from the previous average price target of $285.40. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754085791_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Vulcan Materials. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Codling</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$279.00</td>
<td>$286.00</td>
</tr>
<tr>
<td>Adam Seiden</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$305.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Angel Castillo</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$285.00</td>
<td>$303.00</td>
</tr>
<tr>
<td>Steven Fisher</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$318.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Angel Castillo</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$303.00</td>
<td>$273.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Vulcan Materials. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Vulcan Materials compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Vulcan Materials's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Vulcan Materials's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/VMC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Vulcan Materials analyst ratings.</strong></a></p>
<h2>Delving into Vulcan Materials's Background</h2>
<p>Vulcan Materials is the United States' largest producer of construction aggregates (crushed stone, sand, and gravel). Its largest markets include Texas, California, Virginia, Tennessee, Georgia, Florida, North Carolina, and Alabama. In 2024, Vulcan sold 219.9 million tons of aggregates, 13.6 million tons of asphalt mix, and 3.6 million cubic yards of ready-mix. As of Dec. 31, 2023, the company had nearly 16 billion tons of aggregates reserves.</p>
<h3>Vulcan Materials's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Vulcan Materials's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of <strong>5.75%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Materials sector.</p>
<p><strong>Net Margin:</strong> Vulcan Materials's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>7.89%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Vulcan Materials's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>1.59%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Vulcan Materials's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.76%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Vulcan Materials's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.67</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Where Vulcan Materials Stands With Analysts

<p>In the last three months, 4 analysts have published ratings on AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for AbbVie, revealing an average target of $230.75, a high estimate of $255.00, and a low estimate of $205.00. Marking an increase of 2.21%, the current average surpasses the previous average price target of $225.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754085782_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive AbbVie. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$227.00</td>
<td>$216.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$255.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Gary Nachman</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$236.00</td>
<td>$227.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$205.00</td>
<td>$210.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to AbbVie. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AbbVie compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of AbbVie's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into AbbVie's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ABBV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on AbbVie analyst ratings.</strong></a></p>
<h2>Delving into AbbVie's Background</h2>
<p>AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).</p>
<h3>AbbVie: A Financial Overview</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Growth:</strong> AbbVie displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately <strong>8.39%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> AbbVie's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>9.56%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> AbbVie's ROE excels beyond industry benchmarks, reaching <strong>53.78%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> AbbVie's ROA excels beyond industry benchmarks, reaching <strong>0.94%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>49.22</strong>, caution is advised due to increased financial risk.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ABBV

Expert Outlook: AbbVie Through The Eyes Of 4 Analysts

<p>In the current session, <strong>Reliance Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RS#NYSE">RS</a>)</strong> is trading at $283.43, after a <strong>2.31%</strong> decrease. Over the past month, the stock fell by <strong>12.46%</strong>, and in the past year, by <strong>0.20%</strong>. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1754085727_0.png" alt="Past Year Chart" /></p>

<h3>Evaluating Reliance P/E in Comparison to Its Peers</h3>
<p>The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. </p>
<p>Compared to the aggregate P/E ratio of the <strong>29.88</strong> in the Metals &amp; Mining industry, Reliance Inc. has a lower P/E ratio of <strong>21.01</strong>. Shareholders might be inclined to think that  the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1754085727_1.png" alt="Guage" /></p>

<p>In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions. </p>


Intraday Update

Markets

P/E Ratio Insights for Reliance

<p>Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Mid-America Apartment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAA#NYSE">MAA</a>) in the last three months.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $168.89, along with a high estimate of $194.00 and a low estimate of $142.00. A 0.52% drop is evident in the current average compared to the previous average price target of $169.78. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754085722_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Mid-America Apartment. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brad Heffern</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$155.00</td>
<td>$158.00</td>
</tr>
<tr>
<td>Michael Goldsmith</td>
<td>UBS</td>
<td>Lowers</td>
<td>Sell</td>
<td>$142.00</td>
<td>$149.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$180.00</td>
<td>$194.00</td>
</tr>
<tr>
<td>Vikram Malhotra</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$161.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Aaron Hecht</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$170.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$171.00</td>
<td>$174.00</td>
</tr>
<tr>
<td>Buck Horne</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$194.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Richard Hightower</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$172.00</td>
<td>$160.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Mid-America Apartment. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Mid-America Apartment compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Mid-America Apartment's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Mid-America Apartment's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MAA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Mid-America Apartment analyst ratings.</strong></a></p>
<h2>Get to Know Mid-America Apartment Better</h2>
<p>Mid-America Apartment Communities Inc or MAA, is a real estate investment trust engaged in the acquisition, operation, and development of multifamily apartment communities located in the southeastern and southwestern United States. The company operates two reportable segments; Same Store includes communities that the Company has owned and have been stabilized for at least a full 12 months as of the first day of the calendar year and Non-Same Store and Other includes recently acquired communities, communities being developed or in lease-up, communities that have been disposed of or identified for disposition, communities that have experienced a casualty loss and stabilized communities that do not meet the requirements to be Same Store communities.</p>
<h3>Mid-America Apartment: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Mid-America Apartment's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>0.11%</strong> as of 30 June, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> Mid-America Apartment's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>19.5%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Mid-America Apartment's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>1.8%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Mid-America Apartment's ROA excels beyond industry benchmarks, reaching <strong>0.91%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Mid-America Apartment's debt-to-equity ratio is below the industry average. With a ratio of <b>0.85</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Expert Outlook: Mid-America Apartment Through The Eyes Of 9 Analysts

<p>Canadian Natural Res (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNQ#NYSE">CNQ</a>) has outperformed the market over the past 5 years by 14.17% on an annualized basis producing an average annual return of 27.67%. Currently, Canadian Natural Res has a market capitalization of $64.81 billion. </p>
<p><strong>Buying $100 In CNQ:</strong> If an investor had bought $100 of CNQ stock 5 years ago, it would be worth <strong>$349.55</strong> today based on a price of $30.96 for CNQ at the time of writing.</p>
<h3>Canadian Natural Res's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754085696_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much $100 Invested In Canadian Natural Res 5 Years Ago Would Be Worth Today

<p>DA Davidson  analyst Brent Thielman   maintains EMCOR Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EME#NYSE">EME</a>) with a Buy and raises the price target from $515 to $725.</p>


DA Davidson Maintains Buy on EMCOR Group, Raises Price Target to $725

<p>DA Davidson  analyst Brent Thielman   maintains KBR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBR#NYSE">KBR</a>) with a Buy and lowers the price target from $72 to $65.</p>


DA Davidson Maintains Buy on KBR, Lowers Price Target to $65

<p>DA Davidson  analyst Brent Thielman   maintains Quanta Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) with a Neutral and raises the price target from $305 to $395.</p>


DA Davidson Maintains Neutral on Quanta Services, Raises Price Target to $395

<p><a href="https://www.bloomberg.com/news/articles/2025-08-01/wal-mart-de-mexico-ceo-ignacio-caride-resigns-abruptly">https://www.bloomberg.com/news/articles/2025-08-01/wal-mart-de-mexico-ceo-ignacio-caride-resigns-abruptly</a></p>


'Wal-Mart de Mexico CEO Ignacio Caride Resigns Abruptly'- Bloomberg

<p>DA Davidson  analyst Brent Thielman   maintains WillScot Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSC#NASDAQ">WSC</a>) with a Buy and lowers the price target from $45 to $40.</p>


DA Davidson Maintains Buy on WillScot Holdings, Lowers Price Target to $40

<p>DA Davidson  analyst Gil Luria   maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Buy and raises the price target from $230 to $265.</p>


AMZN

DA Davidson Maintains Buy on Amazon.com, Raises Price Target to $265

<p>Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) has outperformed the market over the past 10 years by 9.98% on an annualized basis producing an average annual return of 21.54%. Currently, Apple has a market capitalization of $3.04 trillion. </p>
<p><strong>Buying $100 In AAPL:</strong> If an investor had bought $100 of AAPL stock 10 years ago, it would be worth <strong>$701.49</strong> today based on a price of $202.50 for AAPL at the time of writing.</p>
<h3>Apple's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754084728_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


AAPL

Here's How Much You Would Have Made Owning Apple Stock In The Last 10 Years

<p>DA Davidson  analyst Gil Luria   maintains Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Buy and maintains $250 price target.</p>


DA Davidson Maintains Buy on Apple, Maintains $250 Price Target

Biotech

Press Releases

aTyr Pharma to Participate in April Investor Conferences

Health Care

aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025

Earnings

aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update

aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

aTyr Pharma to Present at Upcoming Investor Conferences

aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)

Comments

aTyr Pharma

Actualités

Dernières nouvelles pour aTyr Pharma (NASDAQ:ATYR) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL